Compare AstraZeneca plc (AZN) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? AstraZeneca plc trades at $166.95 (market cap $253.13B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $32.61. The key difference: AstraZeneca plc pays a 1.92% dividend while Direxion Daily 20 Year Treasury Bull 3X Shares pays none, and AstraZeneca plc is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| AZN | TMF | |
|---|---|---|
Market Cap | $253.13B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $209.48 | $44.14 |
52-Week Low | $137.44 | $31.85 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
TMF, a leveraged ETF tracking long-term US Treasuries, trades at $32.81, down 1.83% today. Technical indicators are bearish overall, with moving averages signaling strong selling pressure, though oscillators show some bullish momentum. The stock lacks traditional fundamental metrics like P/E or revenue due to its ETF structure, relying instead on underlying bond performance and interest rate trends.
Outlook remains volatile, driven by Federal Reserve policy shifts and bond market fluctuations. Risks include daily leverage decay and interest rate sensitivity. Analyst sentiment is mixed, with some seeing opportunity at bond market lows, while others caution against long-term holds due to amplified losses in rising rate environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
